Business
Share Price Movement
Share Price Movement.
About this update from Valirx Plc
[{"type":"text","content":"\n \n \n RNS Number : 6970L\n ValiRx PLC\n 01 May 2020\n \n \n \n \n \n \n \n \n \n \n \n \n \n VALIRX PLC\n \n \n (\"ValiRx\", the \"Company\" or the \"Group\")\n \n \n \n \n \n Share Price Movement\n \n \n \n \n \n \n London, UK\n \n ., 1 May 2020: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company notes the recent movement in its share price.\n \n \n \n \n \n The Company notes that there has been a significant amount of corporate and clinical activity notified in the past 2 weeks.\n \n \n \n \n \n As announced on 1 April 2020 the Company is required to raise further funds in the near future in order to meet its working capital requirements. In the event that the Company undertakes a placing it is likely to be at a significant discount to the Company's current share price.\n \n \n \n \n \n This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.\n \n \n \n \n \n \n \n \n For more information, please contact:\n \n \n \n \n \n \n \n \n ValiRx plc\n \n \n \n \n Tel: +44 (0) 20 7073 2628\n \n \n \n www.valirx.com\n \n \n \n \n \n \n \n Kevin Alexander\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Cairn Financial Advisers LLP (Nominated Adviser)\n \n \n \n \n Liam Murray / Jo Turner / Ludovico Lazzaretti\n \n \n \n \n \n \n \n Tel: +44 (0) 20 7213 0880\n \n \n \n \n \n \n Peterhouse Capital Limited (Sole Broker)\n \n \n Duncan Vasey / Lucy Williams / Eran Zucker \n \n \n \n \n \n \n \n Tel: +44 (0) 20 7469 0930\n \n \n \n \n \n Notes for Editors\n \n \n \n \n \n \n \n \n About ValiRx \n \n \n ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in \"precision\" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.\n \n \n \n \n \n The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in th...